Route and Duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment.

[1]  P. D. de Vries,et al.  Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomised, double-blind, placebo-controlled, non-inferiority trial. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  C. Keighley,et al.  Out Of Hospital And In Hospital Management Of Cellulitis Requiring Intravenous Therapy , 2019, International journal of general medicine.

[3]  Jacob J. Baker,et al.  Evaluation of a multifaceted approach to antimicrobial stewardship education methods for medical residents , 2019, Infection Control & Hospital Epidemiology.

[4]  A. Cheng,et al.  Lessons Learned From a Randomized Controlled Trial of Short-Course Intravenous Antibiotic Therapy for Erysipelas and Cellulitis of the Lower Limb (Switch Trial) , 2019, Open forum infectious diseases.

[5]  R. Brindle,et al.  Assessment of Antibiotic Treatment of Cellulitis and Erysipelas: A Systematic Review and Meta-analysis. , 2019, JAMA dermatology.

[6]  J. Timsit,et al.  The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  M. Wilcox,et al.  Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection , 2019, Antimicrobial Agents and Chemotherapy.

[8]  S. Eltonsy,et al.  Continuous cefazolin infusion versus cefazolin plus probenecid for the ambulatory treatment of uncomplicated cellulitis: A retrospective cohort study. , 2019, Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada.

[9]  Grace C. Lee,et al.  Age-based health and economic burden of skin and soft tissue infections in the United States, 2000 and 2012 , 2018, PloS one.

[10]  M. Blanes,et al.  Cellulitis in adult patients: A large, multicenter, observational, prospective study of 606 episodes and analysis of the factors related to the response to treatment , 2018, PloS one.

[11]  Tim Friede,et al.  Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies , 2018, BMC Medical Research Methodology.

[12]  K. Thomas,et al.  Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey , 2018, The British journal of dermatology.

[13]  H. Trau,et al.  Corticosteroid Therapy in Combination with Antibiotics for Erysipelas. , 2018, The Israel Medical Association journal : IMAJ.

[14]  S. Choi,et al.  Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection , 2017, Infection & chemotherapy.

[15]  F. Babl,et al.  Evaluating an admission avoidance pathway for children in the emergency department: outpatient intravenous antibiotics for moderate/severe cellulitis , 2017, Emergency Medicine Journal.

[16]  D. Lye,et al.  Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore , 2017, BMC Infectious Diseases.

[17]  J. Okhovat,et al.  Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis , 2017, JAMA dermatology.

[18]  N. Chan-Tompkins,et al.  Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients , 2016, BMC Infectious Diseases.

[19]  D. Kroshinsky,et al.  Cellulitis: A Review. , 2016, JAMA.

[20]  R. Silverman,et al.  Intravenous Home Infusion Therapy Instituted From a 24-Hour Clinical Decision Unit For Patients With Cellulitis. , 2016, The American journal of emergency medicine.

[21]  J. Saunders,et al.  The management of cellulitis in emergency departments: antibiotic-prescribing practices and adherence to practice guidelines in Ireland , 2016, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[22]  R. Bousfield,et al.  OPAT for cellulitis: its benefits and the factors that predispose to longer treatment , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[23]  F. Babl,et al.  Who Can Have Parenteral Antibiotics at Home?: A Prospective Observational Study in Children with Moderate/Severe Cellulitis , 2016, The Pediatric infectious disease journal.

[24]  S. Skrede,et al.  Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study , 2015, Open forum infectious diseases.

[25]  A. Wallace,et al.  Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010 , 2015, BMC Infectious Diseases.

[26]  C. Kunin,et al.  Clinical and microbiological characteristics of purulent and non-purulent cellulitis in hospitalized Taiwanese adults in the era of community-associated methicillin-resistant Staphylococcus aureus , 2015, BMC Infectious Diseases.

[27]  Herman Chiu,et al.  Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. , 2015, The Journal of antimicrobial chemotherapy.

[28]  D. Nathwani,et al.  Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  T. Jenkins,et al.  Clinical Characteristics and Antibiotic Utilization in Pediatric Patients Hospitalized With Acute Bacterial Skin and Skin Structure Infection , 2014, The Pediatric infectious disease journal.

[30]  G. Moran,et al.  Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. , 2014, The Lancet. Infectious diseases.

[31]  E. P. Dellinger,et al.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Mark G Thomas,et al.  Oral Clindamycin Compared With Sequential Intravenous and Oral Flucloxacillin in the Treatment of Cellulitis in Adults: A Randomized, Double-Blind Trial , 2014 .

[33]  Bryan C. Knepper,et al.  Avoidable antibiotic exposure for uncomplicated skin and soft tissue infections in the ambulatory care setting. , 2013, The American journal of medicine.

[34]  J. Bogner,et al.  Moxifloxacin in Complicated Skin and Skin Structure Infections (cSSSIs): A Prospective, International, Non-Interventional, Observational Study , 2013, Advances in Therapy.

[35]  Anita F. Das,et al.  Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. , 2013, JAMA.

[36]  Benjamin A Lipsky,et al.  A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes , 2012, BMC Infectious Diseases.

[37]  Jan V Hirschmann,et al.  Lower limb cellulitis and its mimics: part I. Lower limb cellulitis. , 2012, Journal of the American Academy of Dermatology.

[38]  W. Waring,et al.  Variability of antimicrobial prescribing in patients with acute cellulitis , 2012, European Journal of Clinical Pharmacology.

[39]  Bryan C. Knepper,et al.  Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. , 2011, Archives of internal medicine.

[40]  J. Garioch,et al.  Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care , 2011, The British journal of dermatology.

[41]  P. Mehler,et al.  Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  S. Miyakis,et al.  Risk stratification and outcome of cellulitis admitted to hospital. , 2010, The Journal of infection.

[43]  A. Kam,et al.  Pediatric Cellulitis: Success of Emergency Department Short-Course Intravenous Antibiotics , 2010, Pediatric emergency care.

[44]  Dawn Andrews,et al.  Baseline factors predicting the duration of intravenous antibiotic therapy for cellulitis in an outpatient setting , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[45]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[46]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[47]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[48]  S. Gouin,et al.  Prospective evaluation of the management of moderate to severe cellulitis with parenteral antibiotics at a paediatric day treatment centre , 2008, Journal of paediatrics and child health.

[49]  M. Bader,et al.  Risk Factors of Cellulitis Treatment Failure with Once-Daily Intravenous Cefazolin Plus Oral Probenecid , 2007, Southern medical journal.

[50]  J. Higgins,et al.  Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. , 2007, International journal of epidemiology.

[51]  L. Baddour,et al.  A predictive model of recurrent lower extremity cellulitis in a population-based cohort. , 2007, Archives of internal medicine.

[52]  G. Tositti,et al.  Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. , 2005, The Journal of infection.

[53]  N. Marlow,et al.  Emergency department management of home intravenous antibiotic therapy for cellulitis , 2005, Emergency Medicine Journal.

[54]  R. Seaton,et al.  Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. , 2005, The Journal of antimicrobial chemotherapy.

[55]  A. Viera,et al.  Understanding interobserver agreement: the kappa statistic. , 2005, Family medicine.

[56]  D. Dooley,et al.  Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. , 2004, Archives of internal medicine.

[57]  Benjamin A Lipsky,et al.  Managing skin and soft tissue infections: expert panel recommendations on key decision points. , 2003, The Journal of antimicrobial chemotherapy.

[58]  F. Gudiol,et al.  Factors Associated with Complications and Mortality in Adult Patients Hospitalized for Infectious Cellulitis , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[59]  L. Vaillant,et al.  Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial , 2002, BMJ : British Medical Journal.

[60]  J. Turnidge,et al.  Home‐based treatment of cellulitis with twice‐daily cefazolin , 1998, The Medical journal of Australia.

[61]  D. Maclellan,et al.  Case survey of management of cellulitis in a tertiary teaching hospital , 1996 .

[62]  Gerding Dn,et al.  Does antibiotic restriction prevent resistance? , 1996, New horizons.

[63]  L. Montero.  A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. , 1996, The Journal of antimicrobial chemotherapy.

[64]  J. Roujeau,et al.  Roxithromycin verseus penicillin in the treatment of erysipelas in adults: a comparative study , 1992, The British journal of dermatology.

[65]  R. Daniel.  Azithromycin, Erythromycin and Cloxacillin in the Treatment of Infections of Skin and Associated Soft Tissues , 1991, The Journal of international medical research.

[66]  R. Kiani.  Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[67]  T. Hooton,et al.  Microbiologic evaluation of cutaneous cellulitis in adults. , 1986, Archives of internal medicine.

[68]  J. Lefrock,et al.  Noncomparative trial of ticarcillin plus clavulanic acid in skin and soft tissue infections. , 1985, The American journal of medicine.

[69]  C. Jorup-Rönström,et al.  The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas , 1984, Infection.

[70]  W. Snodgrass,et al.  Sulphanilamide in the Treatment of Erysipelas , 1937, British medical journal.

[71]  W. Snodgrass,et al.  Prontosil in Erysipelas , 1937, British medical journal.

[72]  Northgate.  Hospital Episode Statistics , 2006 .

[73]  C. Frampton,et al.  Lower limb cellulitis: features associated with length of hospital stay. , 2006, The Journal of infection.

[74]  D. Gerding,et al.  Does antibiotic restriction prevent resistance? , 1996, New horizons.

[75]  A. Rodriguez-Solares,et al.  A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. , 1993, The Journal of antimicrobial chemotherapy.